DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Clinical trial NCT06313086 · RECRUITING

Trial details

NCT number: NCT06313086
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2024-03-13
Primary completion: 2025-12-01
Enrollment: 442

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.